HFSA's 21st Annual Scientific Meeting

Sep 16, 2017 ‐ Sep 19, 2017


HFSA’s Annual Scientific Meeting is planned by and for cardiologists, nurses, pharmacists, and scientists, with something of interest to everyone on the heart failure team.

The 2017 program includes significant content in advanced heart failure, pharmacology, patient care, diagnosis and management, devices and technology, and bench-to-bedside translational science. It includes sessions for those new to heart failure and for established specialists.


Sessions

HFpEF Current and Emerging Approaches to Diagnosis and Evaluation of HFpEF

Sep 16, 2017 10:30am ‐ Sep 16, 2017 12:00pm

Credits: None available.

HFpEF remains a challenging clinical syndrome to even define, let alone treat. This session will review how to define HFpEF for clinical practice and study design, how to integrate current diagnostic tools optimally, and how to apply existing and new technologies to advanced phenotyping of HFpEF.

Learning Objectives:

  1. Review the clinical and physiologic information provided by currently available diagnostic techniques in the evaluation of HFpEF.
  2. Assess the indications for techniques in the clinical evaluation of patients with HFPEF.
  3. Recognize the potential of these techniques for the assessment of drug effects in clinical trials.

Speaker(s):
  • Payman Zamani, MD, MTR, FHFSA, FACC, Assistant Professor of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
  • James C. Fang, MD, FHFSA, Professor of Medicine; Chief, Division of Cardiovascular Medicine; Executive Director, Cardiovascular Service Line, University of Utah
  • Tom Sarma , MD, Department of Medicine, Division of Cardiology, University of Texas Southwestern Medical Center
  • Amil M. Shah , MD, MPH, , Assistant Professor of Medicine - Harvard Medical School, Brigham and Women's Hospital
  • Julio Chirinos, MD, PhD, University of Pennsylvania
  • Barry A. Borlaug, MD, Mayo Clinic

JOINT SESSION (HRS): Contemporary EP Issues in HF

Sep 16, 2017 10:30am ‐ Sep 16, 2017 12:00pm

Credits: None available.

Speaker(s):
  • Douglas Mann, MD, PhD, Washington University at St. Louis School of Medicine
  • Camille G. Frazier-Mills, MD, MHS, Assistant Professor, Clinical Cardiac Electrophysiology, Duke University Medical Center, Durham, NC
  • Melissa Robinson, MD, FACC, FHRS, Clinical Associate Professor of Medicine, University of Washington
  • Jeffrey Arkles, MD, Assistant Professor, University of Pennsylvania

Call the Shock Team Call the Shock Team

Preview Available

Call the Shock Team

Sep 16, 2017 10:30am ‐ Sep 16, 2017 12:00pm

Credits: None available.

Speaker(s):

JOINT SESSION (MYOCARDITIS FOUNDATION): The Elephant in the Rheum: The Autoimmune Cardiomyopathies

Sep 16, 2017 10:30am ‐ Sep 16, 2017 12:00pm

Credits: None available.

Speaker(s):

Satellite 1Satellite 1

Preview Available

Satellite 1

Sep 16, 2017 12:15pm ‐ Sep 16, 2017 2:15pm

Credits: None available.


Joint Session (SCMR)  Joint Session (SCMR)

Preview Available

Joint Session (SCMR)

Sep 16, 2017 2:30pm ‐ Sep 16, 2017 4:00pm

Credits: None available.


How to Develop and Accomplish Research: A Symposium for Early Career Professionals

Sep 16, 2017 2:30pm ‐ Sep 16, 2017 4:00pm

Credits: None available.

Speaker(s):

Excellence in Translational Science - Emerging Inotrope Strategies: Bench to Bedside

Sep 16, 2017 2:30pm ‐ Sep 16, 2017 4:00pm

Credits: None available.

Speaker(s):
  • Benjamin Prosser, PhD, Departament of Physiology, University of Pennsylvania - Perelman School of Medicine
  • Daniel Judge, MD, FHFSA, Director, Cardiovascular Genetics, Medical University of South Carolina
  • Patrick Most, MD, Professor, Heidelberg University Hospital, Germany

JOINT SESSION (AHA)– What Can You Do To Prevent HF?

Sep 16, 2017 2:30pm ‐ Sep 16, 2017 4:00pm

Credits: None available.

Thus, there is an unmet need for new inotropic strategies. This session will review the clinical need for new inotropic strategies, the basic science underpinning novel strategies for enhancing cardiac contractility, and emerging date from proof-of-concept pre-clinical clinical research. Target audience is primarily physician and non-physician practitioners who care for patients with severe or unstable heart failure syndromes. Additionally, this session will be of value for clinical trainees and scientists involved with early and late therapeutic drug development.

Speaker(s):
  • Mark Drazner, MD, FHFSA, University of Texas Southwestern
  • Nancy Albert, PhD, CCNS, CCRN, NE-BC, FAHA, FCCM, FHFSA, FAAN, Cleveland Clinic

JOINT SESSION (AAHFN): Heart Failure Readmissions: Is There Anything New?

Sep 16, 2017 2:30pm ‐ Sep 16, 2017 4:00pm

Credits: None available.

Speaker(s):
Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content